Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362111 | 0.89 | CYP3A4 (0.31) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL22286996 | 0.89 | CYP3A4 (0.31) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL14366680 | 0.82 | CYP3A4 (0.30) | CYP3A4GAACYP2C19 | |
| SCHEMBL14392453 | 0.80 | NPC1 (0.32) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL25939349 | 0.80 | — | — | |
| SCHEMBL2419398 | 0.79 | CYP3A4 (0.43) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL17387673 | 0.79 | CYP3A4 (0.43) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL24741970 | 0.76 | NPC1 (0.50) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL4712988 | 0.76 | SMN1; SMN2 (0.46) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL25346203 | 0.76 | SMN1; SMN2 (0.33) | CYP3A4GAACYP2C19NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-1689721-B1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1641455-B1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-7300944-B2 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300944-B2 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1689721-A1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1641455-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005051919-A1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005000304-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | CYP3A4 460/4885GAA 3567/4885CYP2C19 199/4885 |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | CYP3A4 469/4885GAA 3526/4885CYP2C19 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.